← All Articles
Biotech

Dire Wolves Are Real Again. Is a Woolly Mammoth Next?

Colossal Biosciences' three gene-edited dire wolves are now a functioning pack that hunts together. The company's next target, the woolly mammoth, just got pushed back years — a reminder of how much harder de-extinction gets the further back you go.

An abstract illustration of a wolf silhouette formed from strands of DNA

Illustration: FrontierTech.news

A decade ago, "de-extinction" was a phrase mostly used in science fiction and TED talks. In 2026, it has a functioning pack of animals attached to it: three gene-edited wolves, bred to carry traits of a species that vanished roughly 12,000 years ago, now hunting together in the wild-ish way their extinct namesakes once did.

The dire wolves are thriving

Colossal Biosciences' three dire wolves — Romulus, Remus, and Khaleesi — have reached full maturity and now live together as an established pack. Recent health exams, including CT scans and MRI imaging, found them healthy enough that the company's Chief Animal Officer described the team as confirming they can move ahead with population expansion. The pack has successfully coordinated hunts on smaller prey and is now working up to larger animals like deer, and Colossal is now planning to breed additional pups, building out infrastructure at multiple facilities to support a growing population.

What "de-extinction" actually means here

It's worth being precise about what this is and isn't. Colossal didn't resurrect an exact genetic copy of an extinct dire wolf — it edited a living relative's genome, a gray wolf, to express a set of dire-wolf-associated traits identified from ancient DNA. The result is an animal that looks and behaves like scientists' best reconstruction of a dire wolf, built on a modern species' genetic chassis, not a literal clone. That distinction matters for understanding the much harder project the company has taken on next.

The much harder mammoth problem

Colossal originally targeted a mammoth-like calf birth around 2027–2028. CEO Ben Lamm now says: "We are thinking it will be in the early 2030s." The reason is that the genetics turned out to be far more complicated than expected — the number of gene edits believed necessary to give an elephant embryo mammoth traits like a thick coat, shortened ears, and a shorter tail has grown from an initial estimate of roughly 60 genes to more than 150, and that number is still climbing as researchers map the regulatory DNA governing hair growth and cold-weather physiology, not just the protein-coding genes themselves. The company has taken interim steps to de-risk the science: it created gene-edited "woolly mice" in 2025 to test individual edits, and plans "woolly pigs" next, to validate modifications on a larger mammal before ever attempting an actual elephant surrogate pregnancy.

The number of gene edits believed necessary for a mammoth-like elephant has grown from roughly 60 to more than 150 — and researchers say that number is still climbing.

Enjoying this?

Get one weekly email summarizing the developments that actually matter across AI, energy, biotech, space, blockchain, and climate technology.

Newsletter Coming Soon

The business case hiding inside the spectacle

Colossal's work has produced a byproduct with more immediate commercial relevance than a mammoth: elephants carry cancer-resistance genes, particularly TP53 and LIF6, that researchers have studied through this project and believe could inform human cancer research. The company has spun that research thread into a separate AI-driven venture, Astromech — a sign that even Colossal itself is hedging the mammoth's long, uncertain timeline with nearer-term scientific value.

The honest read

The dire wolf result is genuinely impressive and real: a functioning pack of animals expressing traits of an extinct species, alive and hunting together in 2026. But it's also the easier end of what de-extinction can currently do — editing a close living relative toward a phenotype, not reconstructing a genome from scratch. The mammoth project is the harder test of whether this approach scales to a species separated from its closest living relative by a much deeper evolutionary gap, and Colossal's own shifting timeline — and ballooning gene-edit count — is the clearest evidence yet of just how much harder that test really is.

Frequently Asked Questions

Are Colossal Biosciences' dire wolves actually dire wolves?

Not in a strict genetic sense. They're gray wolves gene-edited to express traits associated with dire wolves based on ancient DNA — a reconstruction of the phenotype built on a living relative's genome, not a literal clone of the extinct species.

When will Colossal's woolly mammoth project produce an actual mammoth-like elephant?

Not soon. The original target of 2027–2028 has slipped to the early 2030s, according to CEO Ben Lamm, as the number of gene edits believed necessary grew from about 60 to more than 150 and is still increasing.

How are the dire wolves doing today?

All three — Romulus, Remus, and Khaleesi — have reached full maturity, passed comprehensive health exams, and now hunt together as an established pack, working up from small prey to larger animals like deer. Colossal is now planning to breed additional pups.

Does this de-extinction research have any use beyond reviving extinct species?

Yes. Research into elephant cancer-resistance genes (TP53 and LIF6), conducted as part of the mammoth project, has potential human cancer research applications and led Colossal to spin out a separate AI-driven venture, Astromech.

What's next, explained.

One email a week. AI, blockchain, energy, biotech, space, and climate tech — the developments that actually matter, minus the noise.